Equities research analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for GW Pharmaceuticals PLC-‘s earnings, with estimates ranging from ($1.80) to $1.68. GW Pharmaceuticals PLC- reported earnings of ($1.26) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 89.7%. The company is expected to report its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full year earnings of ($4.76) per share for the current fiscal year, with EPS estimates ranging from ($7.32) to $2.24. For the next year, analysts forecast that the company will post earnings of ($0.44) per share, with EPS estimates ranging from ($2.79) to $5.88. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.48) by $0.80. The firm had revenue of $39.20 million for the quarter, compared to analysts’ expectations of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The firm’s revenue was up 1189.5% on a year-over-year basis. During the same period in the prior year, the company earned ($3.12) EPS.

A number of research firms recently commented on GWPH. BidaskClub cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Morgan Stanley reaffirmed a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Tuesday, April 9th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $185.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, February 27th. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $193.00 price objective for the company in a report on Thursday, April 11th. Finally, Oppenheimer downgraded shares of GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 price objective for the company. in a report on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. GW Pharmaceuticals PLC- presently has an average rating of “Buy” and a consensus price target of $205.40.

NASDAQ:GWPH traded down $1.50 on Wednesday, reaching $176.71. The stock had a trading volume of 261,250 shares, compared to its average volume of 459,330. The firm has a market cap of $5.33 billion, a price-to-earnings ratio of -16.73 and a beta of 2.56. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00.

In other GW Pharmaceuticals PLC- news, insider Adam D. George sold 258,324 shares of GW Pharmaceuticals PLC- stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $16.10, for a total value of $4,159,016.40. Following the completion of the transaction, the insider now owns 268,324 shares of the company’s stock, valued at $4,320,016.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Christopher J. Tovey sold 200,736 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $16.14, for a total value of $3,239,879.04. Following the completion of the sale, the chief operating officer now owns 203,239 shares in the company, valued at $3,280,277.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,521,576 shares of company stock valued at $23,249,266. 5.50% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Deutsche Bank AG lifted its stake in GW Pharmaceuticals PLC- by 18.2% in the fourth quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock valued at $26,350,000 after buying an additional 41,593 shares during the last quarter. Tekla Capital Management LLC lifted its stake in GW Pharmaceuticals PLC- by 45.3% in the fourth quarter. Tekla Capital Management LLC now owns 63,345 shares of the biopharmaceutical company’s stock valued at $6,169,000 after buying an additional 19,747 shares during the last quarter. Osborn Williams & Donohoe LLC bought a new stake in GW Pharmaceuticals PLC- in the first quarter valued at $129,000. Chartwell Investment Partners LLC bought a new stake in GW Pharmaceuticals PLC- in the first quarter valued at $2,380,000. Finally, Exane Derivatives bought a new stake in GW Pharmaceuticals PLC- in the first quarter valued at $28,000. Institutional investors own 79.07% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: What are gap-down stocks?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.